Optimal scanning time window for 18F-FP-(+)-DTBZ ( 18F-AV-133) summed uptake measurements

Nuclear Medicine and Biology

Volumn 38, Issue 8, 2011, Pages 1149-1155

  Lin, Kun Ju ^a,b   Lin, Wey Yil ^a   Hsieh, Chia Ju ^a,b   Weng, Yi Hsin ^a   Wey, Shiaw Pyng ^a,b   Lu, Chin Song ^a   Skovronsky, Daniel ^d   Yen, Tzu Chen ^a   Chang, Chee Jen ^a   Kung, Mei Ping ^a,c   Hsiao, Ing Tsung ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

Optimal scanning time window; Parkinson's disease; PET; Vesicular monoamine transporter II

Indexed keywords

9 FLUOROPROPYLDIHYDROTETRABENAZINE F 18; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG UPTAKE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; PUTAMEN;

AGED; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; OCCIPITAL LOBE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; TETRABENAZINE; TIME FACTORS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 82655162159     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.05.010     Document Type: Article

References (20)

1. Lin K.J., Weng Y.H., Wey S.P., Hsiao I.T., Lu C.S., Skovronsky D., et al. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med 2010, 51:1480-1485.
2. Okamura N., Villemagne V.L., Drago J., Pejoska S., Dhamija R.K., Mulligan R.S., et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med 2010, 51:223-228.
3. Frey K.A., Koeppe R.A., Kilbourn M.R., Vander Borght T.M., Albin R.L., Gilman S., et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996, 40:873-884.
4. Zhou Y., Resnick S.M., Ye W., Fan H., Holt D.P., Klunk W.E., et al. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. NeuroImage 2007, 36:298-312.
5. Huang S.C., Barrio J.R., Phelps M.E. Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. J Cereb Blood Flow Metab 1986, 6:515-521.
6. McNamee R.L., Yee S.H., Price J.C., Klunk W.E., Rosario B., Weissfeld L., et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 2009, 50:348-355.
7. Carson R.E., Channing M.A., Blasberg R.G., Dunn B.B., Cohen R.M., Rice K.C., et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 1993, 13:24-42.
8. Carson R.E. PET physiological measurements using constant infusion. Nucl Med Biol 2000, 27:657-660.
9. Dhawan V., Ma Y., Pillai V., Spetsieris P., Chaly T., Belakhlef A., et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 2002, 43:1324-1330.
10. Cohen J. The t test for means. Statistical power analysis for the behavioral sciences 1988, 19-74. Lawrence Erlbaum, Hillsdale, New Jersey. 2nd ed. J. Cohen (Ed.).
11. Tsao H.H., Lin K.J., Juang J.H., Skovronsky D.M., Yen T.C., Wey S.P., et al. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenazine (AV-133) to the vesicular monoamine transporter type 2 in rats. Nucl Med Biol 2010, 37:413-419.
12. Scherman D., Raisman R., Ploska A., Agid Y. [3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem 1988, 50:1131-1136.
13. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990, 10:740-747.
14. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996, 16:834-840.
15. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage 1996, 4:153-158.
16. McArdle B.H. The significance of differences between means. A simulation study. Comp Biochem Physiol A Comp Physiol 1987, 87(4):979-982.
17. Nye J.A., Votaw J.R., Jarkas N., Purselle D., Camp V., Bremner J.D., et al. Compartmental modeling of 11C-HOMADAM binding to the serotonin transporter in the healthy human brain. J Nucl Med 2008, 49:2018-2025.
18. Wardak M., Wong K.P., Shao W., Dahlbom M., Kepe V., Satyamurthy N., et al. Movement correction method for human brain PET images: application to quantitative analysis of dynamic 18F-FDDNP scans. J Nucl Med 2010, 51:210-218.
19. Szabo J. Organization of the ascending striatal afferents in monkeys. J Comp Neurol 1980, 189:307-321.
20. Morrish P.K., Rakshi J.S., Bailey D.L., Sawle G.V., Brooks D.J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998, 64:314-319.